|
1
|
Fleshner NE, Herr HW, Stewart AK, Murphy
GP, Mettlin C and Menck HR: The National Cancer Data Base report on
bladder carcinoma. The American College of Surgeons Commission on
Cancer and the American Cancer Society. Cancer. 78:1505–1513. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Babjuk M, Oosterlinck W, Sylvester R,
Kaasinen E, Bohle A, Palou-Redorta J and Roupret M: EAU guidelines
on non-muscle-invasive urothelial carcinoma of the bladder, the
2011 update. Actas Urol Esp. 36:389–402. 2012.(In Spanish).
|
|
3
|
Di Stasi SM, Valenti M, Verri C, Liberati
E, Giurioli A, Leprini G, Masedu F, Ricci AR, Micali F and
Vespasiani G: Electromotive instillation of mitomycin immediately
before transurethral resection for patients with primary urothelial
non-muscle invasive bladder cancer: a randomised controlled trial.
Lancet Oncol. 12:871–879. 2011.
|
|
4
|
DeGraff DJ, Clark PE, Cates JM, Yamashita
H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK,
Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D and
Matusik RJ: Loss of the urothelial differentiation marker FOXA1 is
associated with high grade, late stage bladder cancer and increased
tumor proliferation. PLoS One. 7:e366692012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kaufman DS, Shipley WU and Feldman AS:
Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Massague J: TGFβ in cancer. Cell.
134:215–230. 2008.
|
|
7
|
Gatza CE, Oh SY and Blobe GC: Roles for
the type III TGF-β receptor in human cancer. Cell Signal.
22:1163–1174. 2010.
|
|
8
|
Siegel PM and Massague J: Cytostatic and
apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev
Cancer. 3:807–821. 2003.
|
|
9
|
Dong M, How T, Kirkbride KC, Gordon KJ,
Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR and Blobe GC: The
type III TGF-β receptor suppresses breast cancer progression. J
Clin Invest. 117:206–217. 2007.
|
|
10
|
Turley RS, Finger EC, Hempel N, How T,
Fields TA and Blobe GC: The type III transforming growth factor-β
receptor as a novel tumor suppressor gene in prostate cancer.
Cancer Res. 67:1090–1098. 2007.
|
|
11
|
Hempel N, How T, Dong M, Murphy SK, Fields
TA and Blobe GC: Loss of betaglycan expression in ovarian cancer:
role in motility and invasion. Cancer Res. 67:5231–5238. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gordon KJ, Dong M, Chislock EM, Fields TA
and Blobe GC: Loss of type III transforming growth factor β
receptor expression increases motility and invasiveness associated
with epithelial to mesenchymal transition during pancreatic cancer
progression. Carcinogenesis. 29:252–262. 2008.
|
|
13
|
Finger EC, Turley RS, Dong M, How T,
Fields TA and Blobe GC: TβRIII suppresses non-small cell lung
cancer invasiveness and tumorigenicity. Carcinogenesis. 29:528–535.
2008.
|
|
14
|
Cooper SJ, Zou H, Legrand SN, Marlow LA,
von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V, Tun HW,
Blobe GC, Wood CG and Copland JA: Loss of type III transforming
growth factor-β receptor expression is due to methylation silencing
of the transcription factor GATA3 in renal cell carcinoma.
Oncogene. 29:2905–2915. 2010.
|
|
15
|
Gatza CE, Holtzhausen A, Kirkbride KC,
Morton A, Gatza ML, Datto MB and Blobe GC: Type III TGF-β receptor
enhances colon cancer cell migration and anchorage-independent
growth. Neoplasia. 13:758–770. 2011.
|
|
16
|
Ploeg M, Aben KK and Kiemeney LA: The
present and future burden of urinary bladder cancer in the world.
World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
18
|
Criswell TL, Dumont N, Barnett JV and
Arteaga CL: Knockdown of the transforming growth factor-β type III
receptor impairs motility and invasion of metastatic cancer cells.
Cancer Res. 68:7304–7312. 2008.
|
|
19
|
Elliott RL and Blobe GC: Role of
transforming growth factor β in human cancer. J Clin Oncol.
23:2078–2093. 2005.
|
|
20
|
Pardali K and Moustakas A: Actions of
TGF-β as tumor suppressor and pro-metastatic factor in human
cancer. Biochim Biophys Acta. 1775:21–62. 2007.
|
